Lykos Therapeutics Faces Setback as FDA Rejects Midomafetamine for PTSD Treatment
Lykos Therapeutics, a U.S.-based biotech firm, has expressed concern over the impact of the FDA’s...
Chugai Seeks Approval for Elevidys Gene Therapy in Japan, Targeting Duchenne Muscular Dystrophy
Chugai Pharmaceutical Co., Ltd. (TYO: 4519), a subsidiary of Roche, has submitted a product approval...
Staidson Launches Phase Ia Trial for STSP-0902 Injection in Oligoasthenozoospermia
Staidson (Beijing) Pharmaceutical Co., Ltd. (SHE: 300204) has announced that it has received approval from...
Jiangsu Hengrui Secures NMPA Approval for Clinical Trials of SHR-2106 in Primary Sjögren’s Syndrome
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that it has received clinical trial...
Lepu Scientech Secures NMPA Approval for MemoSORB Biodegradable Atrial Septal Defect Occluder
Lepu Scientech Medical Technology (Shanghai) Co., Ltd. (HKG: 2291) has announced that it has received...
Sino Medical Secures Moroccan Approvals for NC Rockstar Catheter and HT Supreme Stent System
Sino Medical Sciences Technology Inc. (SHA: 688108), a prominent player in China’s medical device sector,...
Vimgreen Pharma Launches Phase II Trial for A2AR Antagonist VG081821AC in Parkinson’s Disease
Zhejiang-based Vimgreen Pharma has announced the launch of a Phase II clinical trial for its...
Gilead Secures FDA Accelerated Approval for Livdelzi in Liver Disease Treatment
Gilead Sciences Inc. (NASDAQ: GILD) has received accelerated approval from the U.S. FDA for its...
Astellas Pharma Secures UK Approval for First-in-Class Gastric Cancer Therapy Vyloy
Astellas Pharma (TYO: 4503), a leading Japanese pharmaceutical company, has secured market approval in the...
GSK’s Ma Zheng to Depart as Head of Communication and Government Affairs in China
Ma Zheng, the head of communication and government affairs for GSK plc (NYSE: GSK) in...
Shanghai Sanyou Medical to Acquire Full Control of SMTP Technology for RMB 415.7 Million
Shanghai Sanyou Medical Co., Ltd. (SHA: 688085), based in China, is set to acquire the...
Shandong Buchang Pharmaceuticals Partners with Lancet for BC001 Licensing in Eurasia
Shandong Buchang Pharmaceuticals Co., Ltd. (SHA: 603858), based in China, has announced plans to enter...
Biogen and Eisai Secure UAE Approval for Alzheimer’s Therapy Leqembi
Biogen Inc. (NASDAQ: BIIB), based in the U.S., and Japan’s Eisai Co., Ltd. have announced...
Shaanxi Leads New Provincial Alliance for Volume-Based Procurement of Medical Products
The Shaanxi Public Resources Trading Center has announced the formation of a provincial alliance for...
CStone to Manufacture Gavreto Locally Following NMPA Approval, Expanding Market Presence
CStone Pharmaceuticals (HKG: 2616), a China-based biopharmaceutical company, has received approval from the National Medical...
China’s Sansure Biotech Launches Approved Kit for Alzheimer’s and Cardiovascular Risk Assessment
Sansure Biotech Inc. (SHA: 688289), a China-based leader in molecular diagnostics, has secured marketing approval...
Qilu Pharmaceutical Gains Approval for Generic Dasatinib, Expanding CML Treatment Options in China
Qilu Pharmaceutical, based in China, has received marketing approval for its generic version of Bristol-Myers...
Eli Lilly Unveils $700 Million R&D Center in Boston to Boost Genetic Medicine Efforts
Eli Lilly & Co. (NYSE: LLY) has inaugurated its new R&D center in Boston’s Seaport...
Ascentage Pharma Secures NMPA Approval for Phase III Trial of Lisaftoclax in MDS
Ascentage Pharma (HKG: 6855), based in China, has received approval from the National Medical Products...
Enhertu Gains Conditional Approval in China for Advanced HER2-Positive Gastric Cancer
Enhertu (trastuzumab deruxtecan), an HER2-targeted antibody-drug conjugate co-developed by AstraZeneca (NASDAQ: AZN, LON: AZN) and...